{"id":"nct:NCT05803421","kind":"trial","title":"A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk","authors":["Eli Lilly and Company"],"author_count":1,"year":2023,"published":"2023-04-07","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT05803421","source_url":"https://clinicaltrials.gov/study/NCT05803421","archive_url":"https://space-kitty.com/papers/nct:NCT05803421","updated":"2026-04-17","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Type 2 Diabetes","Obesity","Overweight or Obesity","Overweight","Cardiovascular Diseases","Chronic Kidney Disease"],"details":{"acronym":"ACHIEVE-4","status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":2749,"sponsor":"Eli Lilly and Company","conditions":["Type 2 Diabetes","Obesity","Overweight or Obesity","Overweight","Cardiovascular Diseases","Chronic Kidney Disease"],"interventions":["DRUG: Orforglipron","DRUG: Insulin Glargine"],"start_date":"2023-04-03","start_date_type":"ACTUAL","primary_completion_date":"2026-03-16","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[{"slug":"glp1-metabolic","title":"GLP-1 & Incretin Therapies: State of the Field (October 2026)","url":"https://space-kitty.com/dossiers/glp1-metabolic"}]}